Achieving cannabis cessation - Evaluating N-acetylcysteine treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the national institute on drug abuse clinical trials network

Contemporary Clinical Trials

Volumn 39, Issue 2, 2014, Pages 211-223

  McClure, Erin A ^a   Sonne, Susan C ^a   Winhusen, Theresa ^b   Carroll, Kathleen M ^c   Ghitza, Udi E ^d   McRae Clark, Aimee L ^a   Matthews, Abigail G ^e   Sharma, Gaurav ^e   Van Veldhuisen, Paul ^e   Vandrey, Ryan G ^f   Levin, Frances R ^g   Weiss, Roger D ^h,i   Lindblad, Robert ^e   Allen, Colleen ^e   Mooney, Larissa J ^j   Haynes, Louise ^a   Brigham, Gregory S ^b   Sparenborg, Steve ^d   Hasson, Albert L ^j   Gray, Kevin M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e EMMES CORPORATION   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^h MCLEAN HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Cannabis; Clinical study design; Marijuana; N acetylcysteine; Pharmacotherapy; Randomized trials

Indexed keywords

ACETYLCYSTEINE; CANNABIS; PLACEBO;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENETIC SCREENING; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; GENETICS; MARIJUANA ABUSE; METHODOLOGY; MIDDLE AGED; SMOKING; UNITED STATES;

ACETYLCYSTEINE; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; GENETIC TESTING; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); RESEARCH DESIGN; SMOKING; UNITED STATES; YOUNG ADULT;

EID: 84908574915     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.08.011     Document Type: Article

References (106)

1. Substance abuse and mental health services administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings 2013, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Rockville, MD.
2. Budney A.J., Moore B.A. Development and consequences of cannabis dependence. J Clin Pharmacol 2002, 42:28S-33S.
3. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391.
4. Substance abuse and mental health data archive. Treatment Episode Data Set: Admissions (TEDS-A) 2012. Substance Abuse and Mental Health Services Administration 2013, United States Department of Health and Human Services, Ann Arbor, MI.
5. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the future national results on drug use: 2012 overview, key findings on adolescent drug use 2013, Institute for Social Research, University of Michigan, Ann Arbor, MI.
6. Davis M.L., Powers M.B., Handelsman P., Medina J.L., Zvolensky M., Smits J.A. Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof 2014.
7. Budney A.J., Roffman R., Stephens R.S., Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007, 4:4-16.
8. McRae A.L., Budney A.J., Brady K.T. Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat 2003, 24:369-376.
9. Kadden R.M., Litt M.D., Kabela-Cormier E., Petry N.M. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007, 32:1220-1236.
10. Hart C.L. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend 2005, 80:147-159.
11. Vandrey R., Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009, 23:543-553.
12. Weinstein A.M., Gorelick D.A. Pharmacological treatment of cannabis dependence. Curr Pharm Des 2011, 17:1351-1358.
13. Benyamina A., Lecacheux M., Blecha L., Reynaud M., Lukasiewcz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother 2008, 8:479-491.
14. Danovitch I., Gorelick D.A. State of the art treatments for cannabis dependence. Psychiatr Clin North Am 2012, 35:309-326.
15. Carroll K.M., Rounsaville B.J. A perfect platform: combining contingency management with medications for drug abuse. Am J Drug Alcohol Abuse 2007, 33:343-365.
16. Gray K.M., Carpenter M.J., Baker N.L., DeSantis S.M., Kryway E., Hartwell K.J., et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012, 169:805-812.
17. Mason B.J., Crean R., Goodell V., Light J.M., Quello S., Shadan F., et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012, 37:1689-1698.
18. Levin F.R., Mariani J.J., Brooks D.J., Pavlicova M., Cheng W., Nunes E.V. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011, 116:142-150.
19. Allsop D.J., Copeland J., Lintzeris N., Dunlop A.J., Montebello M., Sadler C., et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014, 71:281-291.
20. Gass J.T., Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008, 75:218-265.
21. Kalivas P.W., Lalumiere R.T., Knackstedt L., Shen H. Glutamate transmission in addiction. Neuropharmacology 2009, 56(Suppl. 1):169-173.
22. Gipson C.D., Reissner K.J., Kupchik Y.M., Smith A.C., Stankeviciute N., Hensley-Simon M.E., et al. Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. Proc Natl Acad Sci U S A 2013, 110:9124-9129.
23. LaLumiere R.T., Kalivas P.W. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 2008, 28:3170-3177.
24. McFarland K., Lapish C.C., Kalivas P.W. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003, 23:3531-3537.
25. Kalivas P.W., Volkow N.D. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry 2011, 16:974-986.
26. Olive M.F., Cleva R.M., Kalivas P.W., Malcolm R.J. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012, 100:801-810.
27. Hoffman A.F., Lupica C.R. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. J Neurophysiol 2001, 85:72-83.
28. Pistis M., Muntoni A.L., Pillolla G., Gessa G.L. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 2002, 15:1795-1802.
29. Doherty J., Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 2003, 3:46-53.
30. Robbe D., Alonso G., Manzoni O.J. Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens. Ann N Y Acad Sci 2003, 1003:212-225.
31. Schoffelmeer A.N., Hogenboom F., Wardeh G., De Vries T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 2006, 51:773-781.
32. Hoffman A.F., Laaris N., Kawamura M., Masino S.A., Lupica C.R. Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors. J Neurosci 2010, 30:545-555.
33. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L., et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 2002, 948:155-158.
34. Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001, 21:109-116.
35. Parolaro D., Vigano D., Rubino T. Endocannabinoids and drug dependence. Curr Drug Targets CNS Neurol Disord 2005, 4:643-655.
36. Baker D.A., McFarland K., Lake R.W., Shen H., Tang X.C., Toda S., et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003, 6:743-749.
37. Moran M.M., McFarland K., Melendez R.I., Kalivas P.W., Seamans J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005, 25:6389-6393.
38. Madayag A., Lobner D., Kau K.S., Mantsch J.R., Abdulhameed O., Hearing M., et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007, 27:13968-13976.
39. Moussawi K., Zhou W., Shen H., Reichel C.M., See R.E., Carr D.B., et al. Reversing cocaine-induced synaptic potentiation provides enduring protection from relapse. Proc Natl Acad Sci U S A 2011, 108:385-390.
40. Reichel C.M., Moussawi K., Do P.H., Kalivas P.W., See R.E. Chronic N-acetylcysteine during abstinence or extinction after cocaine self-administration produces enduring reductions in drug seeking. J Pharmacol Exp Ther 2011, 337:487-493.
41. Amen S.L., Piacentine L.B., Ahmad M.E., Li S.J., Mantsch J.R., Risinger R.C., et al. Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology 2011, 36:871-878.
42. Zhou W., Kalivas P.W. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry 2008, 63:338-340.
43. Knackstedt L.A., LaRowe S., Mardikian P., Malcolm R., Upadhyaya H., Hedden S., et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009, 65:841-845.
44. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000, 22:209-221.
45. Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988, 319:1557-1562.
46. Berk M., Malhi G.S., Gray L.J., Dean O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013, 34:167-177.
47. McClure E.A., Gipson C.D., Malcolm R.J., Kalivas P.W., Gray K.M. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 2014, 28:95-106.
48. National Institutes of Health Principles of drug addiction treatment: a research-based guide 2012, National Institute on Drug Abuse, Bethesda, MD. 3rd ed.
49. Haney M., Bedi G., Cooper Z.D., Glass A., Vosburg S.K., Comer S.D., et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 2013, 73:242-248.
50. de Dios M.A., Vaughan E.L., Stanton C.A., Niaura R. Adolescent tobacco use and substance abuse treatment outcomes. J Subst Abuse Treat 2009, 37:17-24.
51. Peters E.N., Budney A.J., Carroll K.M. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction 2012, 107:1404-1417.
52. Wright J.M., Htun Y., Leong M.G., Forman P., Ballard R.C. Evaluation of the use of calendar blister packaging on patient compliance with STD syndromic treatment regimens. Sex Transm Dis 1999, 26:556-563.
53. Huang H.Y., Maguire M.G., Miller E.R., Appel L.J. Impact of pill organizers and blister packs on adherence to pill taking in two vitamin supplementation trials. Am J Epidemiol 2000, 152:780-787.
54. Simmons D., Upjohn M., Gamble G.D. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care 2000, 23:153-156.
55. Anton R.F. New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res 1996, 20:3A-9A.
56. Malcolm R., Kajdasz D.K., Herron J., Anton R.F., Brady K.T. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend 2000, 60:161-168.
57. Farmer K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999, 21:1074-1090. [discussion 3].
58. Matsuyama J.R., Mason B.J., Jue S.G. Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts. Ann Pharmacother 1993, 27:851-855.
59. Carroll K.M., Easton C.J., Nich C., Hunkele K.A., Neavins T.M., Sinha R., et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol 2006, 74:955-966.
60. Kamon J., Budney A., Stanger C. A contingency management intervention for adolescent marijuana abuse and conduct problems. J Am Acad Child Adolesc Psychiatry 2005, 44:513-521.
61. Stanger C., Budney A.J., Kamon J.L., Thostensen J. A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug Alcohol Depend 2009, 105:240-247.
62. Budney A.J., Moore B.A., Rocha H.L., Higgins S.T. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006, 74:307-316.
63. Gray K.M., Carpenter M.J., Baker N.L., Hartwell K.J., Lewis A.L., Hiott D.W., et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat 2011, 40:77-86.
64. Roll J.M., Higgins S.T. A within-subject comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Drug Alcohol Depend 2000, 58:103-109.
65. Croft J.R., Festinger D.S., Dugosh K.L., Marlowe D.B., Rosenwasser B.J. Does size matter? Salience of follow-up payments in drug abuse research. IRB 2007, 29:15-19.
66. Festinger D.S., Marlowe D.B., Dugosh K.L., Croft J.R., Arabia P.L. Higher magnitude cash payments improve research follow-up rates without increasing drug use or perceived coercion. Drug Alcohol Depend 2008, 96:128-135.
67. Vandrey R., Bigelow G.E., Stitzer M.L. Contingency management in cocaine abusers: a dose-effect comparison of goods-based versus cash-based incentives. Exp Clin Psychopharmacol 2007, 15:338-343.
68. Olmstead T.A., Petry N.M. The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine- or opioid-dependent outpatients. Drug Alcohol Depend 2009, 102:108-115.
69. McCarty D., Fuller B., Kaskutas L.A., Wendt W.W., Nunes E.V., Miller M., et al. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend 2008, 92:200-207.
70. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33. (quiz 4-57).
71. Association A.P. Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
72. First MS R., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. SCID-I/P 1994, Biometrics Research, New York State Psychiatric Institute, New York.
73. Wilens T.E., Spencer T.J. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010, 122:97-109.
74. Zulauf C.A., Sprich S.E., Safren S.A., Wilens T.E. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep 2014, 16:436.
75. Schmidt L.E., Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol 2001, 51:87-91.
76. Huestis M.A., Cone E.J. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 1998, 22:445-454.
77. Schwilke E.W., Gullberg R.G., Darwin W.D., Chiang C.N., Cadet J.L., Gorelick D.A., et al. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction 2011, 106:499-506.
78. Moran C.L., Le V.H., Chimalakonda K.C., Smedley A.L., Lackey F.D., Owen S.N., et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011, 83:4228-4236.
79. Sobell L.C., Sobell M.B., Leo G.I., Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988, 83:393-402.
80. Mariani J.J., Brooks D., Haney M., Levin F.R. Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend 2011, 113:249-251.
81. Allsop D.J., Norberg M.M., Copeland J., Fu S., Budney A.J. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011, 119:123-129.
82. Heishman S.J., Evans R.J., Singleton E.G., Levin K.H., Copersino M.L., Gorelick D.A. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend 2009, 102:35-40.
83. Heishman S.J., Singleton E.G., Liguori A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 2001, 96:1023-1034.
84. Stephens R.S., Roffman R.A., Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000, 68:898-908.
85. Franken I.H., Hendriksa V.M., van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav 2002, 27:675-685.
86. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
87. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002, 52:69-77.
88. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213.
89. Trivedi M.H., Wisniewski S.R., Morris D.W., Fava M., Gollan J.K., Warden D., et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry 2011, 72:757-764.
90. Posner K., Brent D., Lucas C., Gould M., Stanley B., Brown G., et al. Columbia-Suicide Severity Rating Scale (C-SSRS) 2007.
91. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991, 86:1119-1127.
92. Marzullo L. An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr 2005, 17:239-245.
93. Mucomyst [package insert] 2007, Bristol-Myers Squibb Company, New York City, NY.
94. Bailey B., McGuigan M.A. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med 1998, 31:710-715.
95. Food and Drug Administration Investigational New Drug Application (IND) April, 2013.
96. Hallgren K.A., Witkiewitz K. Missing data in alcohol clinical trials: a comparison of methods. Alcohol Clin Exp Res 2013, 37:2152-2160.
97. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
98. Campbell A.N., Nunes E.V., Matthews A.G., Stitzer M., Miele G.M., Polsky D., et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled Trial. Am J Psychiatry 2014, 171(6):683-690.
99. Subramaniam G.A., Warden D., Minhajuddin A., Fishman M.J., Stitzer M.L., Adinoff B., et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry 2011, 50:1120-1128.
100. Cropsey K.L., Lane P.S., Hale G.J., Jackson D.O., Clark C.B., Ingersoll K.S., et al. Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug Alcohol Depend 2011, 119:172-178.
101. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
102. Shoptaw S., Kintaudi P.C., Charuvastra C., Ling W. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend 2002, 66:217-224.
103. Najavits L.M., Gastfriend D.R., Barber J.P., Reif S., Muenz L.R., Blaine J., et al. Cocaine dependence with and without PTSD among subjects in the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Am J Psychiatry 1998, 155:214-219.
104. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001, 57:120-125.
105. LaRowe S.D., Kalivas P.W., Nicholas J.S., Randall P.K., Mardikian P.N., Malcolm R.J. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict 2013, 22:443-452.
106. Grant J.E., Odlaug B.L., Kim S.W. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010, 20:823-828.